| Cat. No. |
Product Name |
Information |
| PC-38340 |
Avotaciclib
CDK1 inhibitor
|
Avotaciclib (BEY1107) is a potent, selective CDK1 (Cyclin-Dependent Kinase 1) inhibitor, inhibits self-replication of cancer stem cells and is a candidate for pancreatic cancer treatment. |
| PC-73446 |
Tanuxiciclib
CDK inhibitor
|
Tanuxiciclib is a potent cyclin dependent kinase (CDK) inhibitor. |
| PC-73414 |
Eciruciclib
CDK inhibitor
|
Eciruciclib is a potent cyclin dependent kinase (CDK) inhibitor with antineoplastic activities. |
| PC-73257 |
ASP9822
CDK7 inhibitor
|
ASP9822 is a novel potent selective CDK7 inhibitor with IC50 of 4.3 nM, with anti-cancer activity. |
| PC-73186 |
NCT02
CCNK-CDK12 degrader
|
NCT02 is a small moelcule that induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK and its complex partner CDK12. |
| PC-73102 |
SR4835
CDK12/13 inhibitor
|
SR-4835 (SR4835) is a potent, highly selective dual inhibitor of CDK12 and CDK13 with IC50 of 98 and 4.9 nM, respectively. |
| PC-72894 |
GFB-12811
CDK5 inhibitor
|
GFB-12811 (GFB12811) is a potent, highly selective CDK5 inhibitor with IC50 of 2.3 nM. |
| PC-72777 |
SY-5609
CDK7 inhibitor
|
SY-5609 (SY5609) is a highly potent, selective, noncovalent and orally available inhibitor of CDK7 with Kd of 0.07 nM in SPR assays (binding to CDK7/Cyclin H). |
| PC-72776 |
Senexin C
CDK8/19 inhibitor
|
Senexin C is a novel potent, selective and orally bioavailable CDK8/19 inhibitor with Kd of 1.4 and 2.9 nM for CDK8/CycC and CDK19/CycC, respectively. |
| PC-72755 |
AS-0141
CDC7 inhibitor
|
Monzosertib (AS 0141) is a potent, selective, orally bioavailable CDC7 inhibitor with IC50 of 2.4 nM. |
| PC-72673 |
BRD6688
HDAC2 inhibitor
|
BRD6688 is a potent, kinetically selective HDAC2 inhibitor with IC50 of 21/100 nM for HDAC1/2, >115-fold selectivity versus HDAC3. |
| PC-72642 |
SY-1365
CDK7 inhibitor
|
SY-1365 (Mevociclib, SY1365) is a potent, selective, covalent CDK7 inhibitor with Ki of 17.4 nM. |
